Prevalencia de caries y estado periodontal de los niÑos y adolescentes de Navarra (2002)

Introducción (fundamento y objetivo): En Navarra se realiza un seguimiento epidemiológico de la caries dental y su tratamiento desde el año 1987, antes de la puesta en marcha del programa PADI en 1991. El objetivo de este trabajo ha sido conocer el estado de salud dental y periodontal de la población infantil y adolescente de Navarra en 2002. Método: Encuesta epidemiológica sobre una muestra al azar de escolares de 1º, 3º y 6º de Enseñanza Primaria y 2º ESO, de 1566 sujetos. Los exámenes clínicos fueron realizados por examinadores calibrados (Kappa 0,93) en los colegios utilizando equipamiento portátil. El estudio estadístico se realizó con una base de datos Microsoft Acces, con el paquete estadístico SPSS versión 10 para Windows. Resultados: La prevalencia de caries en dentición temporal a los 6 años fue de 35,4% (cod 1,28) y en permanente a los 14 años 50,7%. La media CAOD en los cuatro grupos etarios fue 0,04; 0,27; 0,75 y 1,36 respectivamente. Los índices de restauración (IR) 16,7%, 48,1%, 77,3% y 78,7%. El estado periodontal, sanos (6 sext. ) 9,1%, sangrado 86,3%, cálculo 17,2%. Conclusión: La prevalencia de caries sigue siendo alta pero la media de dientes afectados baja; la tendencia respecto de 1997 es a aumentar en dentición temporal y a disminuir en permanente.

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Background: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 μg or placebo once-daily. Patients were required to have a postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of ≤70% and FEV1 <80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George"s Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. Results: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement ≥4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. Conclusion: Aclidinium is effective and well tolerated in patients with moderate to severe COPD. Trial registration: ClinicalTrials.gov: NCT00363896 ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).

1.48 and 1.84 µm thulium emissions in monoclinic KGd(WO4)2 single crystals

By exciting at 788 nm, we have characterized the near infrared emissions of trivalent thulium ions in monoclinic KGd(WO4)2 single crystals at 1.48 and 1.84 mm as a function of dopant concentration from 0.1% to 10% and temperature from 10 K to room temperature. We used the reciprocity method to calculate the maximum emission cross-section of 3.0310220 cm2 at 1.838 mm for the polarization parallel to the Nm principal optical direction. These results agrees well with the experimental data. Experimental decay times of the 3H4!3F4 and 3F4!3H6 transitions have been measured as a function of thulium concentration.